fentaNYL 2 mcg/mL and bupivacaine 0 — Class II drug recall D-0016-2024
Terminated recall by Central Admixture Pharmacy Services Inc, reported 2023-10-11, distributed nationwide. Lack of assurance of sterility:
| Recall number | D-0016-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Central Admixture Pharmacy Services Inc, San Diego, CA, United States |
| Recall initiated | 2023-09-21 |
| Classified | 2023-10-04 |
| Reported by FDA | 2023-10-11 |
| Terminated | 2025-03-19 |
| Distributed | Nationwide (US) |
| Quantity | 60 |
| Reason classes | sterility |
| NDC | 71286-2081-01 |
| Lot numbers | 17-275929 |
| Expiration dates | 2023-10-12 |
Product
fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volume = 250 mL, Total fentaNYL 500 mcg/250 mL, 250 mL bag, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2081-1
Reason for recall
Lack of assurance of sterility:
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0016-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.